MA53643A - Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 - Google Patents

Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6

Info

Publication number
MA53643A
MA53643A MA053643A MA53643A MA53643A MA 53643 A MA53643 A MA 53643A MA 053643 A MA053643 A MA 053643A MA 53643 A MA53643 A MA 53643A MA 53643 A MA53643 A MA 53643A
Authority
MA
Morocco
Prior art keywords
dioxocyclobutenylamino
picolinamide
hydroxy
substituted
useful
Prior art date
Application number
MA053643A
Other languages
English (en)
Inventor
Andrew Christopher Flick
Brian Stephen Gerstenberger
Daniel Wei-Shung Kung
Vincent Michael Lombardo
James John Mousseau
Philippe Marcel Nuhant
Jr Ralph Pelton Robinson
Daniel Copley Schmitt
Mark Edward Schnute
Atli Thorarensen
John Isidro Trujillo
Rayomand Jal Unwalla
Huixian Wu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA53643A publication Critical patent/MA53643A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA053643A 2018-09-21 2019-09-18 Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 MA53643A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734486P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
MA53643A true MA53643A (fr) 2021-12-29

Family

ID=68051869

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053643A MA53643A (fr) 2018-09-21 2019-09-18 Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6

Country Status (32)

Country Link
US (3) US10975065B2 (fr)
EP (1) EP3852879A1 (fr)
JP (1) JP6989729B2 (fr)
KR (2) KR102615234B1 (fr)
CN (2) CN116874466A (fr)
AR (1) AR116464A1 (fr)
AU (1) AU2019344107B2 (fr)
BR (1) BR112021003956A2 (fr)
CA (1) CA3055805A1 (fr)
CL (1) CL2021000683A1 (fr)
CO (1) CO2021003391A2 (fr)
CR (1) CR20210146A (fr)
CU (1) CU20210016A7 (fr)
DO (1) DOP2021000045A (fr)
EA (1) EA202190586A1 (fr)
EC (1) ECSP21018584A (fr)
GE (2) GEP20237476B (fr)
IL (1) IL281634B2 (fr)
MA (1) MA53643A (fr)
MX (1) MX2021003318A (fr)
MY (1) MY209296A (fr)
NI (1) NI202100012A (fr)
NZ (1) NZ773473A (fr)
PE (1) PE20211070A1 (fr)
PH (1) PH12021550554A1 (fr)
PY (1) PY1978496A (fr)
SG (1) SG11202101827RA (fr)
TW (1) TWI754172B (fr)
UA (1) UA128700C2 (fr)
UY (1) UY38379A (fr)
WO (1) WO2020058869A1 (fr)
ZA (1) ZA202101169B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211070A1 (es) * 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6
UA130467C2 (uk) * 2020-04-30 2026-02-25 Ідорсія Фармасьютікалз Лтд Похідні азетидин-3-ілметанолу як модулятори рецептора ccr6
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
KR20240090695A (ko) 2021-10-26 2024-06-21 이도르시아 파마슈티컬스 리미티드 Ccr6 수용체 조절인자
IL312369A (en) * 2021-10-28 2024-06-01 Idorsia Pharmaceuticals Ltd CCR6 receptor modulators
CN116162081B (zh) * 2022-12-13 2024-08-09 药康众拓(江苏)医药科技有限公司 一类氘代吡啶酰胺类ccr6抑制剂药物及用途
WO2024222865A1 (fr) * 2023-04-28 2024-10-31 武汉朗来科技发展有限公司 Composé utilisé comme antagoniste de ccr6, composition pharmaceutique et utilisation associée

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
ES2128774T3 (es) 1994-11-16 1999-05-16 American Home Prod Diaminociclobuten-3,4-dionas.
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
ES2287284T3 (es) 2001-04-16 2007-12-16 Schering Corporation Ciclobuteno-1,2-dionas disustituidas en las posiciones 3,4 como ligandos de receptores de quimiocinas cxc.
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
CN1720240B (zh) * 2002-10-09 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的噻二唑二氧化物和噻二唑氧化物
ATE523506T1 (de) 2005-02-16 2011-09-15 Schering Corp Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität
AU2007233173A1 (en) 2006-03-31 2007-10-11 Janssen Pharmaceutica N.V. 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers
MX2008015004A (es) 2006-05-26 2008-12-05 Abbott Lab Inhibidores de cinasas de tipo polo.
US20080045489A1 (en) 2006-07-07 2008-02-21 Jianhua Chao 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
CA2685529A1 (fr) 2007-04-30 2008-11-06 Abbott Laboratories Inhibiteurs d'enzyme diacylglycerol o-acyltransferase de type 1
ATE554066T1 (de) 2007-06-06 2012-05-15 Novartis Ag Entzündungshemmende substituierte cyclobutendionverbindungen
CN101778836A (zh) 2007-07-05 2010-07-14 先灵公司 在1,2-取代的3,4-二氧-1-环丁烯化合物中控制的晶体大小的方法
WO2009012375A2 (fr) 2007-07-19 2009-01-22 Wyeth Inhibiteurs de la squarate kinase
CN101808990B (zh) 2007-07-24 2012-09-05 百时美施贵宝公司 作为趋化因子受体活性调节剂的哌啶衍生物
JP2010534669A (ja) 2007-07-24 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしての非環式誘導体
CA2706883A1 (fr) 2007-12-04 2009-06-11 Schering Corporation Procedes de traitement de la broncho-pneumopathie chronique obstructive
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (fr) 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2
WO2010131145A1 (fr) * 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
CA2771822C (fr) 2009-09-04 2020-08-11 Daniel A. Erlanson Inhibiteurs de tyrosine kinase de bruton
MX2012005463A (es) 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
JP2014525443A (ja) 2011-08-30 2014-09-29 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物、およびこれらの使用方法
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
ES2715682T3 (es) 2012-12-19 2019-06-05 Novartis Ag Inhibidores de la autotaxina
CN104936949A (zh) 2013-01-25 2015-09-23 百时美施贵宝公司 用于治疗丙型肝炎的squaric衍生物
CA2908098A1 (fr) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Inhibiteurs mk2 et utilisations associees
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US10660909B2 (en) * 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
PE20211070A1 (es) * 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6

Also Published As

Publication number Publication date
PE20211070A1 (es) 2021-06-09
ECSP21018584A (es) 2021-04-29
IL281634A (en) 2021-05-31
CU20210016A7 (es) 2021-10-12
CN112672791A (zh) 2021-04-16
CN116874466A (zh) 2023-10-13
AR116464A1 (es) 2021-05-12
PH12021550554A1 (en) 2022-02-21
KR20210046717A (ko) 2021-04-28
IL281634B1 (en) 2024-10-01
CN112672791B (zh) 2023-10-03
TW202024056A (zh) 2020-07-01
CR20210146A (es) 2021-05-20
US20210206757A1 (en) 2021-07-08
KR102615234B1 (ko) 2023-12-19
CA3055805A1 (fr) 2020-03-21
GEAP202215588A (en) 2022-11-10
MX2021003318A (es) 2021-05-14
US12312344B2 (en) 2025-05-27
US11708360B2 (en) 2023-07-25
US10975065B2 (en) 2021-04-13
JP2021532166A (ja) 2021-11-25
GEP20237476B (en) 2023-03-27
CL2021000683A1 (es) 2021-10-15
UY38379A (es) 2020-04-30
WO2020058869A1 (fr) 2020-03-26
KR102755257B1 (ko) 2025-01-14
US20240368144A1 (en) 2024-11-07
TWI754172B (zh) 2022-02-01
JP6989729B2 (ja) 2022-01-05
CO2021003391A2 (es) 2021-04-08
EA202190586A1 (ru) 2021-07-05
AU2019344107B2 (en) 2022-09-15
EP3852879A1 (fr) 2021-07-28
ZA202101169B (en) 2022-07-27
MY209296A (en) 2025-07-01
NI202100012A (es) 2021-06-22
KR20230175326A (ko) 2023-12-29
NZ773473A (en) 2023-07-28
UA128700C2 (uk) 2024-10-02
SG11202101827RA (en) 2021-04-29
PY1978496A (es) 2020-04-20
BR112021003956A2 (pt) 2021-05-25
US20200095239A1 (en) 2020-03-26
IL281634B2 (en) 2025-02-01
DOP2021000045A (es) 2021-04-30
AU2019344107A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
EP3601239A4 (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
EP3906026A4 (fr) Inhibiteurs irréversibles de l'interaction ménine-mll
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
EP3883570A4 (fr) Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
FR25C1047I1 (fr) Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA53229A (fr) Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA51433A (fr) Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1